子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 酰肼化合物及其制造方法、以及使用它的固化剂、树脂组合物及固化体 | CN201080025073.6 | 2010-05-27 | CN102459155A | 2012-05-16 | 樱庭一郎; 福本邦宏 |
| 本发明提供一种酰肼化合物，其对于具有不饱和键的树脂具有高活性，并且稳定地反应，可以作为固化剂使用，并提供上述酰肼化合物制造方法、以及热固化剂、树脂组合物及固化体。本发明的酰肼化合物含有在分子内具有至少1个酰肼基的结晶性酰肼化合物、和能够与该结晶性酰肼化合物形成络合物的金属元素。本发明的树脂用固化剂包含该酰肼化合物。本发明的树脂组合物包含该固化剂、在分子中具有至少1个不饱和键的树脂、和环氧树脂。本发明的固化体是使该树脂组合物固化而成的。本发明的酰肼化合物的制造方法包括：将在分子内具有至少1个酰肼基的结晶性酰肼化合物、和能够与该结晶性酰肼化合物形成络合物的金属元素加热而得到混合物的工序；对混合物进行恒温处理的工序；将混合物冷却而得到固化体的工序。 | ||||||
| 2 | 合成取代的吡唑的方法 | CN200680027223.0 | 2006-07-21 | CN101300232A | 2008-11-05 | 谭鲁石; J·C·麦克威廉斯; F·W·哈特纳; 吉川直树; 李文捷 |
| 本申请涉及一种式I化合物的合成方法。式I化合物是一种胰高血糖素受体拮抗剂且对于治疗、预防或延缓2型糖尿病的发作是有效的。 | ||||||
| 3 | 一类能够抑制锌离子金属蛋白酶的化合物 | CN200610065730.5 | 2006-03-14 | CN1837169A | 2006-09-27 | 房学迅; 姬海涛; 金峰海; 柳森; 牛凤兰; 史秀娟; 王会铃; 桑清湘; 曹强; 李惟; 王玉宏 |
| 本发明公开了1，2，3－三羟基苯及其衍生物或其药学上可接受的盐用于对锌离子金属蛋白酶的抑制作用(式I)。这些化合物被用来作为锌离子金属蛋白酶(例如，MT1－MMP，明胶酶A，B和胶原酶，matrilysins，金属弹性蛋白酶，stromelysin－1)的有效的选择性抑制剂。这些抑制剂可以被用来调节基质金属蛋白酶(MMPs)、ADAMs、ADAM－TS参与的许多生理及病理过程，例如血管新生，伤口愈合，器官移植，对受精过程和再生能力的控制，骨的重建，疼痛等；可以用来治疗癌症，心血管疾病，关节炎，牙周疾病，多发性硬化症，炎症，子宫内膜异位症，角膜溃疡，细菌性脑膜炎，糖尿病综合症，肾病，神经退行性疾病，AIDS，疱疹，过敏症，子宫内膜异位症，骨质疏松，哮喘等。另外，这些抑制剂还可以用于抗衰老；抗菌；作为细胞外基质/胶原产物、化妆品、美容产品的工业生产的添加剂。这些抑制剂可以用在人，动物以及其他生物体上。 | ||||||
| 4 | 酰肼化合物及其制造方法、以及使用它的固化剂、树脂组合物及固化体 | CN201080025073.6 | 2010-05-27 | CN102459155B | 2015-03-25 | 樱庭一郎; 福本邦宏 |
| 本发明提供一种酰肼化合物，其对于具有不饱和键的树脂具有高活性，并且稳定地反应，可以作为固化剂使用，并提供上述酰肼化合物制造方法、以及热固化剂、树脂组合物及固化体。本发明的酰肼化合物含有在分子内具有至少1个酰肼基的结晶性酰肼化合物、和能够与该结晶性酰肼化合物形成络合物的金属元素。本发明的树脂用固化剂包含该酰肼化合物。本发明的树脂组合物包含该固化剂、在分子中具有至少1个不饱和键的树脂、和环氧树脂。本发明的固化体是使该树脂组合物固化而成的。本发明的酰肼化合物的制造方法包括：将在分子内具有至少1个酰肼基的结晶性酰肼化合物、和能够与该结晶性酰肼化合物形成络合物的金属元素加热而得到混合物的工序；对混合物进行恒温处理的工序；将混合物冷却而得到固化体的工序。 | ||||||
| 5 | 二酰基肼衍生物 | CN00810147.7 | 2000-07-05 | CN1210256C | 2005-07-13 | G·赫尔泽曼; S·谷德曼; H·凯斯勒; C·基普森; G·瑟尤克 |
| 通式(I)的二酰基肼衍生物，其中X，Y，Z，R1，R2和R3具有在权利要求1中列出的意义，和它的生理学上可接受的盐或溶剂化物，它们是整联蛋白抑制剂和可用于抵抗血栓形成，心肌梗塞，冠心病，动脉硬化，炎症，肿瘤，骨质疏松症，感染以及在血管成形术后或在由血管生成所维持或增殖的病理过程中的再狭窄。 | ||||||
| 6 | 二酰基肼衍生物 | CN00810147.7 | 2000-07-05 | CN1360568A | 2002-07-24 | G·赫尔泽曼; S·谷德曼; H·凯斯勒; C·基普森; G·瑟尤克 |
| 通式(I)的二酰基肼衍生物,其中X,Y,Z,R1,R2和R3具有在权利要求1中列出的意义,和它的生理学上可接受的盐或溶剂化物,它们是整联蛋白抑制剂和可用于抵抗血栓形成,心肌梗塞,冠心病,动脉硬化,炎症,肿瘤,骨质疏松症,感染以及在血管成形术后或在由血管生成所维持或增殖的病理过程中的再狭窄。 | ||||||
| 7 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | EP11193098.8 | 2004-02-27 | EP2460786B1 | 2016-01-13 | Hormann, Robert Eugene; Potter, David, W.; Chortyk, Orestes; Tice, Colin, M.; Carlson, Glenn, Richard; Meyer, Andrew; Opie, Thomas, R. |
| The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. | ||||||
| 8 | Hydrazide compounds and methods for producing the same, as well as the curing agent using the same, resin composition and cured body | JP2009139569 | 2009-06-10 | JP4961458B2 | 2012-06-27 | 一郎 櫻庭; 邦宏 福本 |
| Disclosed are: a hydrazide compound which has a high activity on a resin having an unsaturated bond and can react with the resin stably, and which can be used as a curing agent; a process for producing the hydrazide compound; and a heat-curing agent, a resin composition and a cured article. Specifically disclosed are: a hydrazide compound which comprises a crystalline hydrazide compound having at least one hydrazide group in the molecule and a metal element capable of forming a complex with the crystalline hydrazide compound; a curing agent for a resin, which comprises the hydrazide compound; a resin composition comprising the curing agent, a resin having at least one unsaturated bond in the molecule and an epoxy resin; a cured article produced by curing the resin composition; and a process for producing a hydrazide compound, which comprises the steps of heating a crystalline hydrazide compound having at least one hydrazide group in the molecule and a metal element capable of forming a complex with the crystalline hydrazide compound to produce a mixture, carrying out an isothermal treatment of the mixture, and cooling the mixture to produce a solidified material. | ||||||
| 9 | JPS5016336B1 - | JP8493368 | 1968-11-21 | JPS5016336B1 | 1975-06-12 | |
| 10 | ネプリライシン阻害剤 | JP2015561541 | 2014-03-04 | JP2016512195A | 2016-04-25 | エリック フェンスター，; メリッサ フルーリー，; アダム ディー． ヒューズ， |
| 一態様では、本発明は、式(I)(式中、R1〜R5およびXは本明細書で定義された通りである)を有する化合物、または薬学的に許容されるその塩に関する。これらの化合物は、ネプリライシン阻害活性を有する。別の態様では、本発明は、このような化合物を含む薬学的組成物;このような化合物を使用する方法;ならびにこのような化合物を調製するためのプロセスおよび中間体に関する。本発明の化合物は、高血圧および心不全などの状態を処置するための治療剤として有用および有利であると予期されている。 | ||||||
| 11 | エクジソン受容体複合体を通して外因性遺伝子の発現を調節するための生物学的利用能のあるジアシルヒドラジン・リガンド | JP2011286880 | 2011-12-27 | JP5642060B2 | 2014-12-17 | ホーマン，ロバート，ユージン; ポーター，デイビッド，ダブリュー．; チョルティク，オレステス; タイス，コリン，エム．; カールソン，グレン，リチャード; マイヤー，アンドリュー; オピエ，トーマス，アール． |
| 12 | Compounds for the treatment of proliferative disorders | JP2009525584 | 2007-08-20 | JP2010501560A | 2010-01-21 | シー‐キァン シァ; リジュン スン; ショウジュン チェン; ザシャリー デムコ; 圭三 古屋 |
| Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. | ||||||
| 13 | NEPRILYSIN INHIBITORS | US15219478 | 2016-07-26 | US20170015619A1 | 2017-01-19 | Erik Fenster; Melissa Fleury; Adam D. Hughes |
| In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds. | ||||||
| 14 | Neprilysin inhibitors | US14749949 | 2015-06-25 | US09428457B2 | 2016-08-30 | Erik Fenster; Melissa Fleury; Adam D. Hughes |
| In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds. | ||||||
| 15 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | US13954376 | 2013-07-30 | US20140045903A1 | 2014-02-13 | Robert Eugene HORMANN; David W. Potter; Orestes Chortyk; Colin M. Tice; Glenn Richard Carlson; Andrew Meyer; Thomas R. Opie |
| The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. | ||||||
| 16 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | US13953558 | 2013-07-29 | US20130338162A1 | 2013-12-19 | Lijun Sun; Keizo Koya; Shoujun Chen; Zachary Demko; Zhi-Qiang Xia |
| Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. | ||||||
| 17 | Bioavailable Diacylhydrazine Ligands for Modulations the Expression of Exogenous Genes via an Ecdysone Receptor Complex | US13603965 | 2012-09-05 | US20130035487A1 | 2013-02-07 | Robert Eugene HORMANN; David W. Potter; Orestes Chortyk; Colin M. Tice; Glenn Richard Carlson; Andrew Meyer; Thomas R. Opie |
| The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. | ||||||
| 18 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | US13243210 | 2011-09-23 | US20120046322A1 | 2012-02-23 | Robert Eugene HORMANN; David W. Potter; Orestes Chortyk; Colin M. Tice; Glenn Richard Carlson; Andrew Meyer; Thomas R. Opie |
| The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. | ||||||
| 19 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | US12310299 | 2007-08-20 | US20110245262A1 | 2011-10-06 | Lijun Sun; Keizo Koya; Shoujun Chen; Zachary Demko; Zhi-Qiang Xia |
| Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. | ||||||
| 20 | Process for synthesizing a substituted pyrazole | US11988849 | 2006-07-21 | US07709658B2 | 2010-05-04 | Lushi Tan; James Christopher McWilliams; Frederick W. Hartner; Naoki Yoshikawa; Wenji Li |
| The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus. | ||||||
QQ群二维码
意见反馈
意见反馈